Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications.

被引：34

作者：

Boerrigter G. ^{[1
]}

Burnett Jr. J.C. ^{[1
]}

机构：

[1] Mayo Clinic, 200 First Street SW, Rochester, 55905, MN

来源：

Current Heart Failure Reports | 2004年 / 1卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Natriuretic Peptide; Atrial Natriuretic Peptide; Loop Diuretic; Eplerenone; Tolvaptan;

D O I：

10.1007/s11897-004-0020-9

中图分类号：

学科分类号：

摘要：

Various lines of evidence implicate impaired renal function as an important prognostic indicator in patients with congestive heart failure (CHF). Conventional diuretics may aggravate renal dysfunction and can result in neurohumoral activation. Evolving new therapeutic strategies that enhance renal function include administration of B-type natriuretic peptide, adenosine and vasopressin antagonists, and ultrafiltration methods. Prospective studies are needed to evaluate whether these new renal-enhancing strategies will improve patient outcome in CHF.

引用

页码：113 / 120

页数：7

共 120 条

[1] Hillege HL(2000)Renal function, neurohormonal activation, and survival in patients with chronic heart failure Circulation 102 203-210
[2] Girbes AR(2000)The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction J Am Coll Cardiol 35 681-689
[3] de Kam PJ(2004)Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure J Am Coll Cardiol 43 61-67
[4] Dries DL(1999)Hormones and hemodynamics in heart failure N Engl J Med 341 577-585
[5] Exner DV(1995)A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction J Clin Invest 95 1101-1108
[6] Domanski MJ(2000)Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy Physiol Rev 80 277-313
[7] Forman DE(2001)Diuretic therapy and resistance in congestive heart failure Cardiology 96 132-143
[8] Butler J(2001)Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure Am J Med 111 513-520
[9] Wang Y(2000)Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group N Engl J Med 343 246-253
[10] Schrier RW(1997)Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart Am J Physiol 273 H2406-H2414

← 1 2 3 4 5 6 7 8 9 10 →